Leerink Partners Starts Maze Therapeutics (MAZE) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Leerink Partners Starts Maze Therapeutics (MAZE) at Outperform
February 25, 2025 5:30 AM EST
TD Cowen analyst Tyler Van Buren initiates coverage on Maze Therapeutics (NASDAQ: MAZE) with a Buy rating.
The analyst comments "MZE829 (oral APOL1 inhibitor) could address the majority of >1M AKD patients and is ~100x more potent than Vertex's inaxaplin. MZE782 (novel oral... More
February 25, 2025 12:59 AM EST
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Maze Therapeutics (NASDAQ: MAZE) with a Buy rating and a price target of $19.00.
The analyst comments: "Leveraging the companys Compass platform, mgmt has advanced three small molecules into clinical development. These investigational medicines engage genetic targets... More
February 25, 2025 12:58 AM EST
JPMorgan analyst Anupam Rama initiates coverage on Maze Therapeutics (NASDAQ: MAZE) with a Overweight rating and a price target of $30.00.
The analyst comments: "The companys proprietary COMPASS platform has produced multiple shots on goal to date. Indeed, lead asset MZE829 (APOL1 inhibitor) in APOL1 kidney disease (AKD) is currently in a phase 2 study, with initial or first top-line data from one of the three cohorts... More
